Compare NUVL & RH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | RH |
|---|---|---|
| Founded | 2017 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 3.2B |
| IPO Year | 2021 | 1998 |
| Metric | NUVL | RH |
|---|---|---|
| Price | $100.40 | $193.25 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 16 |
| Target Price | $135.00 | ★ $227.33 |
| AVG Volume (30 Days) | 483.4K | ★ 1.2M |
| Earning Date | 10-30-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.11 |
| EPS | N/A | ★ 5.52 |
| Revenue | N/A | ★ $3,409,319,000.00 |
| Revenue This Year | N/A | $12.43 |
| Revenue Next Year | N/A | $8.89 |
| P/E Ratio | ★ N/A | $35.02 |
| Revenue Growth | N/A | ★ 9.74 |
| 52 Week Low | $55.54 | $123.03 |
| 52 Week High | $112.88 | $455.84 |
| Indicator | NUVL | RH |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 70.03 |
| Support Level | $99.38 | $178.61 |
| Resistance Level | $106.65 | $189.68 |
| Average True Range (ATR) | 2.84 | 8.17 |
| MACD | -0.80 | 2.29 |
| Stochastic Oscillator | 14.80 | 91.23 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
RH is a luxury furniture and lifestyle retailer operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories including furniture, lighting, textiles, bath, decor, and children and is growing the presence of its hospitality business with 23 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade via expanding abroad, its World of RH digital platform (highlighting offerings outside of home furnishings), and offerings in architecture, media, and more.